Close Menu

NEW YORK – Concert Genetics and Trapelo Health have agreed to integrate their technology to offer more comprehensive evidence-based molecular decision support for oncology, the companies said Thursday. They will deliver the service through Nashville, Tennessee-based Concert's network of health plans and genomics laboratories.

The firms said that their partnership seeks to improve connectivity and transparency to help clinicians make more informed decisions on molecular testing, cancer treatment, and recommending patients for clinical trials.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.

Sponsored by

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.